Drug Profile
Diazepam intranasal spray
Alternative Names: DZNS; Plumiaz; SK-DZNSLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator SK Holdings
- Developer Acorda Therapeutics
- Class Antiepileptic drugs; Anxiolytics; Benzodiazepines; Benzodiazepinones; Hypnosedatives; Muscle relaxants; Small molecules
- Mechanism of Action GABA A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Epilepsy
Most Recent Events
- 10 Jun 2016 Acorda Therapeutics completes a pharmacokinetics phase I trial in Healthy volunteers in USA (Intranasal, Spray) (NCT02663999)
- 24 May 2016 Discontinued - Preregistration for Epilepsy in USA (Intranasal)
- 29 Feb 2016 Acorda Therapeutics announces intention to submit NDA to the US FDA in 2017 (Acorda Therapeutics, Form 10-K, February 2016)